QVT Financial’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-19,613
| Closed | -$326K | – | 47 |
|
|
2025
Q1 | $326K | Hold |
19,613
| – | – | 0.03% | 37 |
|
|
2024
Q4 | $360K | Hold |
19,613
| – | – | 0.03% | 33 |
|
|
2024
Q3 | $302K | Hold |
19,613
| – | – | 0.03% | 34 |
|
|
2024
Q2 | $319K | Hold |
19,613
| – | – | 0.03% | 32 |
|
|
2024
Q1 | $362K | Hold |
19,613
| – | – | 0.03% | 33 |
|
|
2023
Q4 | $614K | Hold |
19,613
| – | – | 0.03% | 28 |
|
|
2023
Q3 | $409K | Hold |
19,613
| – | – | 0.02% | 35 |
|
|
2023
Q2 | $470K | Hold |
19,613
| – | – | 0.03% | 39 |
|
|
2023
Q1 | $369K | Hold |
19,613
| – | – | 0.02% | 50 |
|
|
2022
Q4 | $312K | Hold |
19,613
| – | – | 0.02% | 49 |
|
|
2022
Q3 | $321K | Hold |
19,613
| – | – | 0.02% | 54 |
|
|
2022
Q2 | $276K | Hold |
19,613
| – | – | 0.02% | 61 |
|
|
2022
Q1 | $475K | Hold |
19,613
| – | – | 0.02% | 64 |
|
|
2021
Q4 | $458K | Hold |
19,613
| – | – | 0.02% | 56 |
|
|
2021
Q3 | $326K | Hold |
19,613
| – | – | 0.02% | 60 |
|
|
2021
Q2 | $478K | Hold |
19,613
| – | – | 0.03% | 52 |
|
|
2021
Q1 | $506K | Hold |
19,613
| – | – | 0.04% | 49 |
|
|
2020
Q4 | $1.05M | Hold |
19,613
| – | – | 0.06% | 48 |
|
|
2020
Q3 | $809K | Hold |
19,613
| – | – | 0.1% | 45 |
|
|
2020
Q2 | $951K | Hold |
19,613
| – | – | 0.16% | 42 |
|
|
2020
Q1 | $829K | Hold |
19,613
| – | – | 0.19% | 43 |
|
|
2019
Q4 | $839K | Hold |
19,613
| – | – | 0.16% | 45 |
|
|
2019
Q3 | $706K | Hold |
19,613
| – | – | 0.15% | 46 |
|
|
2019
Q2 | $524K | Hold |
19,613
| – | – | 0.11% | 46 |
|
|
2019
Q1 | $527K | Buy |
19,613
+4,881
| +33% | +$114K | 0.13% | 43 |
|
|
2018
Q4 | $238K | Hold |
14,732
| – | – | 0.08% | 50 |
|
|
2018
Q3 | $306K | Hold |
14,732
| – | – | 0.08% | 50 |
|
|
2018
Q2 | $225K | Sell |
14,732
-14,004
| -49% | -$250K | 0.06% | 49 |
|
|
2018
Q1 | $646K | Sell |
28,736
-2,310
| -7% | -$64K | 0.07% | 47 |
|
|
2017
Q4 | $935K | Sell |
31,046
-29,486
| -49% | -$943K | 0.05% | 53 |
|
|
2017
Q3 | $2.28M | Sell |
60,532
-61,121
| -50% | -$1.99M | 0.08% | 58 |
|
|
2017
Q2 | $3.39M | Sell |
121,653
-65,402
| -35% | -$1.95M | 0.09% | 56 |
|
|
2017
Q1 | $6.43M | Sell |
187,055
-57,066
| -23% | -$2.01M | 0.2% | 54 |
|
|
2016
Q4 | $7.04M | Buy |
+244,121
| New | +$6.46M | 0.21% | 56 |
|
Other funds holding ACAD
BBA
RI
PAI
QVT Financial's ACAD Position: Q2 2025 in Review
QVT Financial sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 19,613 shares — an estimated $326K sold.
QVT Financial first reported a position in ACAD in Q4 2016 and held it in 34 quarters. The position peaked at $7.04M in Q4 2016. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.
- QVT Financial reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- QVT Financial sold 19,613 Acadia Pharmaceuticals shares in Q2 2025, an estimated $326K.
- QVT Financial first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 34 quarters.
- QVT Financial's Acadia Pharmaceuticals position peaked at $7.04M in Q4 2016.
- 311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.
Based on QVT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.